A Case of Familial Spondyloenchondrodysplasia with Immune Dysregulation Masquerading as Moyamoya Syndrome

Jin Sook Lee, Byung Chan Lim
Ki Joong Kim, Seung-Ki Kim
Ok-Hwa Kim, Joong Gon Kim
Sung-Gyoo Park, Tae-Joon Cho
Jong-Hee Chae

Dear Editor,

Spondyloenchondrodysplasia with immune dysregulation (SPENCDI; OMIM#607944) caused by ACP5 mutations is a rare skeletal dysplasia that was originally described with radiolucent spondylar and metaphyseal lesions. Neurological involvement—including spasticity, developmental delay, intracranial calcification, and leukodystrophy—has subsequently been reported. Moreover, immune dysregulations such as autoimmunity or immune deficiencies have also been documented. Systemic lupus erythematosus (SLE) is also reportedly associated with SPENCDI. Here we report two siblings with ACP5 variants presenting with moyamoya syndrome (MMS) that progressed to SLE.

A 3-year-old boy was admitted for recurrent transient ischemic attacks of monoplegia or hemiplegia on the right or left side, which usually improved within a few hours. Brain MRI and angiography revealed bilateral middle and anterior cerebral arterial stenoses with collateral circulation (Fig. 1A). His developmental milestones were within the normal range for age. No skin rash, oral lesions, or arthritis were noted. The findings of laboratory studies including an immunological workup were normal. He underwent left encephalogaleoperiostal synangiosis with encephaloduroarteriosynangiosis (EDAS) operation, followed 1 month later by a right EDAS operation. Thereafter, multiple burr-hole trephinations were performed on both occipital areas. However, even after revascularization bypass surgery he still complained of transient ischemic attacks, involuntary choreoathetoid movements, and headache. At the age of 6 years he was admitted for fever of unknown origin. Skin lesions suggestive of Raynaud's phenomenon developed (Fig. 1F). Together with leukopenia, antinuclear antibody at 1:160 (homogeneous pattern), anti-ds DNA at 93 IU/mL (normal, 0–10 IU/mL), positivity for anticardiolipin antibody IgM (25.8 MPL units) (normal, <20 MPL units), and C3/C4 levels of 58/9 mg/dL (normal, 70–150/10–35 mg/dL) were found. A renal biopsy was performed because of his persistent hematuria, which showed diffuse proliferative glomerulonephritis, and so he was diagnosed with SLE and lupus nephritis.

Skeletal surveys performed at 9 years of age due to chronic pain in the extremities revealed platyspondyly and metaphyseal dysplasia, suggesting spondyloenchondrodysplasia (Fig. 1C–E). Follow-up neuroimaging findings at the age of 15 years showed an old infarction with cerebromalacia in the left parieto-occipital and both frontal areas, and total obstruction of both the middle and posterior cerebral arteries and distal internal carotid arteries with neovascularization. His older sister developed similar neurological symptoms: MMS (Fig. 1B) and SLE at 8 and 11 years of age, respectively. These skeletal findings prompted us to perform a skeletal dysplasia gene panel, which confirmed compound heterozygous ACP5 variants in the siblings [OMIM*171640, NM_001111035; c.136C>T (p.R46W) and c.449T>A (p. V150E)], which have been reported previously. The unaffected parents were heterozygous

Copyright © 2019 Korean Neurological Association
carriers of each variant. There were increased levels of interferon (IFN)-α and -β as well as dominant Th1 and Th17 responses. Serum cytokines were measured with the Cytokine Bead Array (BD Biosciences, Franklin Lakes, NJ, USA) using the Canto II flow cytometer (BD Biosciences), and serum IFN levels were analyzed by an enzyme-linked immunosorbent assay (eBioscience/Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions (Supplementary Material and Supplementary Fig. 1 in the online-only Data Supplement).

There have been few reports of comorbid angiopathy in patients with SPENCDI, and no reports on SLE presenting with MMS in patients with SPENCDI. The present study has expanded the neurological phenotypic spectrum of SPENCDI, by adding lupus with MMS. This information will help to improve our understanding of the pathophysiology of MMS associated with autoimmune diseases, in combination with several previous reports suggesting that immune responses can contribute to the development of MMS. Therefore, SPENCDI should be considered as a possible underlying cause in patients presenting with early-onset or familial SLE with angiopathies, even when they show only mild skeletal radiological characteristics. Conversely, early neuroimaging screening or follow-up might be needed to prevent cerebrovascularopathy-related neurological abnormalities in SPENCDI patients.

**Supplementary Materials**
The online-only Data Supplement is available with this article at https://doi.org/10.3988/jcn.2019.15.3.407.

**Conflicts of Interest**
The authors have no potential conflicts of interest to disclose.

**Acknowledgements**
This research was supported by a grant of the Korea Health Technology
REFERENCES


